A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

Phase 1

Withdrawn

• Conditions: Gallbladder Carcinoma; Biliary Tract Carcinoma
• Interventions: Drug: MEK 162; Drug: Gemcitabine; Drug: Oxaliplatin

• Registration Number: NCT02105350
• Lead Sponsor: University Health Network, Toronto

Brief Summary

This is a phase I study (an early study to check the safety of a new drug or drug combination) to find the safest and most tolerated dose of the combination of oxaliplatin with gemcitabine and MEK 162 in patients with biliary cancer (including gallbladder cancers and cancers associated with the bile ducts leading from the gallbladder and to and from the liver) that is not curable by surgery and/or has spread beyond the biliary tree (place where cancer started). Everyone will receive the same standard doses of oxaliplatin and gemcitabine but may receive different doses of MEK 162.

MEK 162 is a new drug which plays an important role in the regulation of cell growth and has been shown to shrink tumours in patients with biliary cancer and other types of human cancers. This type of drug has also been shown to shrink tumours when given in combination with cisplatin and gemcitabine in research studies done in animals and in some patients with biliary cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-04-02
• Study First Submitted QC: 2014-04-04
• Study First Posted: 2014-04-07
• Study Start: 2015-06
• Primary Completion: 2015-06
• Study Completion: 2015-06
• Status Verified: 2018-02
• Last Update Submitted: 2018-02-14
• Last Update Posted: 2018-02-19

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Histopathological or cytological diagnosis of non-resectable, recurrent or metastatic biliary tract (intra- or extra-hepatic) or gallbladder carcinoma.
• Have measurable disease.
• Not received prior systemic therapy for advanced biliary cancer.
• Age 18 years of age or older.
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
• Estimated life expectancy is greater than 3 months.
• Have adequate hematological function.
• Have adequate cardiac function.
• All radiology studies performed within 4 weeks prior to the start of therapy.
• No evidence of active uncontrolled infection.
• Ability to understand and willing to sign a written informed consent document.
• Ongoing prior toxicities related to previous treatments received to grade 1 or less at time of registration.
• Able to take oral medications.

Read More

Exclusion Criteria

• Progressing within 6 months of receiving adjuvant treatment for biliary tract cancer.
• Not have received prior chemotherapy for non-resectable or metastatic disease or MEK inhibitor.
• Histopathological or cytological diagnosis of ampullary carcinoma.
• Incomplete recovery from previous surgery.
• Undergoing current treatment with curative intent.
• History of prior malignancy that could interfere with the response evaluation.
• Any evidence of severe or uncontrolled systemic diseases or laboratory findings that may affect participation in the trial.
• Any psychiatric or other disorder likely to impact on informed consent.
• Pregnant or nursing (lactating) women.
• Agree to use highly effective methods of contraception throughout the study and for 6 months after study drug discontinuation.
• Significant cardiac disease.
• History of retinal degenerative disease.
• History of Gilbert's syndrome.
• Known positive serology for HIV, active hepatitis B, and/or active hepatitis C infection.
• Neuromuscular disorders that are associated with elevated creatine kinase.
• Planning on embarking on a new strenuous exercise regimen after first dose of study treatment.
• Impairment of gastrointestinal function or gastrointestinal disease.
• Any other condition that would contraindicate participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MEK 162, gemcitabine, and oxaliplatin	MEK 162	MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.
MEK 162, gemcitabine, and oxaliplatin	Gemcitabine	MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.
MEK 162, gemcitabine, and oxaliplatin	Oxaliplatin	MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.

Primary Outcome Measures

Name	Time	Method
Total incidence of grade 3 and 4 adverse events	2 years
Total rate of grade 3 and 4 adverse events	2 years
Maximum dose level at which 0/3 patients or 1/6 patients experience dose-limiting toxicity	2 years

Secondary Outcome Measures

Name	Time	Method
Number of patients with objective response rate	2 years